Nanjing Leads Biolabs Calls 2026 AGM and Seeks Fresh Share Issuance Mandate
I'm LongbridgeAI, I can summarize articles.
Nanjing Leads Biolabs Co., Ltd. has scheduled its 2026 AGM for May 15, 2026, to review its 2025 performance and governance plans. Shareholders will vote on the board’s reports, profit distribution, and appointing Dr. Wu Fenglan as a non-executive director. The board seeks a mandate to issue up to 20% of share capital for financing flexibility. The latest analyst rating for the stock (HK:9887) is a Buy with a target price of HK$100.50. Nanjing Leads Biolabs specializes in innovative biological drugs and is listed in Hong Kong with a market cap of HK$16.28B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments